Chest, Vol 101, 736-741, Copyright © 1992 by American College of Chest Physicians

ARTICLES

The effects of acetazolamide on the ventilatory response to high altitude hypoxia

NK Burki, SA Khan and MA Hameed
Department of Medicine, University of Kentucky, Lexington.

Acetazolamide treatment ameliorates the symptoms of AMS; however, the mechanism by which this occurs is unclear. To examine the effects of acetazolamide on oxygenation, CO2 responsiveness and ventilatory pattern during acute exposure to HA, we studied two groups of subjects at SL and following rapid (less than 8 h) transport to HA. Acetazolamide or placebo tablets were given to groups 1 and 2, respectively, in a double-blind manner after baseline SL measurements; treatment was continued during HA exposure. There was no difference in the ventilatory pattern at HA, between the two groups. While the Ve achieved in response to CO2 at HA vs SL was much greater in each group the percent change from baseline at HA versus that at SL was not significantly different. The beneficial effects of acetazolamide in AMS are associated with a higher level of ventilation at HA and better oxygenation: CO2 chemosensitivity is not affected by acetazolamide at HA.

This article has been cited by other articles:

				M. Wagenaar, P. Vos, Y. Heijdra, L. Teppema, and H. Folgering Comparison of Acetazolamide and Medroxyprogesterone as Respiratory Stimulants in Hypercapnic Patients With COPD Chest, May 1, 2003; 123(5): 1450 - 1459. [Abstract] [Full Text] [PDF]

				L. Dumont, C. Mardirosoff, and M. R Tramèr Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review BMJ, July 29, 2000; 321(7256): 267 - 272. [Abstract] [Full Text]

				H.-R. Keller, M. Maggiorini, P. Bartsch, and O. Oelz Simulated descent v dexamethasone in treatment of acute mountain sickness: a randomised trial BMJ, May 13, 1995; 310(6989): 1232 - 1235. [Abstract] [Full Text]